SCHEDULE: Barach Trust Boosts Celularity Stake, Gains Board Seats

The Philip & Daniele Barach Family Trust has acquired a significant convertible note and warrants in Celularity Inc., increasing its beneficial ownership to 29.0% and securing two board seats.

Summary

• Amendment No. 3 to Schedule 13D details a significant financing transaction between Celularity Inc. and the Philip & Daniele Barach Family Trust.
• The Trust purchased a $3,210,000 senior secured convertible promissory note (September 2026 Convertible Note) and warrants to purchase 1,177,000 shares of Class A Common Stock at $1.50 per share.
• The Trust also has an option to purchase up to an additional $2,915,531 in convertible notes (Additional September 2027 Convertible Notes) with warrants to purchase up to 1,457,765 shares at $2.00 per share by September 30, 2027.
• This transaction increases the Trust's beneficial ownership of Celularity's Class A Common Stock to 29.0%, representing 9,491,270 shares, including shares issuable upon conversion and exercise of securities.
• As part of the financing, the Trust secured board representation, with Philip Barach appointed to the board, and the Trust has the right to designate two directors.
• The filing also notes amendments to existing convertible notes and warrants, reducing conversion and exercise prices to $1.50 per share.
• The Company has granted the Trust registration rights for its securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a significant financing event and increased board influence for the reporting persons, though it also highlights ongoing financial needs and potential dilution.

Positives

• Significant capital infusion of $3,210,000 into Celularity Inc. through the purchase of a convertible note.
• The Philip & Daniele Barach Family Trust has increased its beneficial ownership to 29.0%, indicating strong conviction.
• The Trust has secured significant corporate governance influence with the right to appoint two directors to Celularity's five-person board.
• Amended terms on existing notes and warrants reduce conversion and exercise prices to $1.50, potentially making them more valuable.
• The company has agreed to provide registration rights for the Trust's securities.

Negatives

• Celularity Inc. continues to rely on convertible debt financing, indicating potential ongoing cash flow challenges.
• The potential for future dilution exists if the Trust exercises its option for additional notes and warrants or converts existing notes.
• The company's ability to spend proceeds from the financing is limited until the board composition meets the requirements of the Board Rights Agreement.
• The convertible notes accrue interest at 10% per annum, increasing to 15% upon an Event of Default, adding to the company's debt burden.

Risks

• Potential for significant dilution of existing shareholders if the convertible notes are converted or warrants are exercised.
• The company's reliance on debt financing may indicate underlying financial instability.
• The terms of the convertible notes and warrants, including potential adjustments to conversion and exercise prices, could impact future share value.
• The Board Rights Agreement imposes limitations on the company's spending and board composition until certain conditions are met.

Future Outlook

The Trust has the option to purchase additional convertible notes and warrants by September 30, 2027. The Reporting Persons reserve the right to change their intentions regarding the Company, including acquiring or disposing of securities, entering derivative transactions, or influencing corporate actions.

Management Comments

• The Reporting Persons expect to evaluate on an ongoing basis the Company's financial condition and prospects and their interest in, and intentions with respect to, the Company and their investment in the securities of the Company.
• The Reporting Persons reserve the right to change their intentions and develop plans or proposals at any time, as they deem appropriate.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy in the biotechnology and life sciences sector where early-stage companies often rely on structured financing rounds involving convertible debt and warrants, especially when seeking board influence and control.

Comparison to Industry Standards

• The structure of the financing, involving convertible notes and warrants, is typical for early-stage or growth-stage companies in the biotech sector seeking capital without immediate equity dilution at a fixed price.
• The inclusion of board rights is a standard feature in significant debt or equity financings to ensure investor confidence and oversight.
• The interest rate of 10% (potentially rising to 15%) on the convertible notes is within the typical range for high-risk, high-reward investments in this industry, though on the higher end.
• The exercise prices of $1.50 and $2.00 for warrants are common, often set above the prevailing market price at the time of issuance to provide upside potential for investors.

Management Changes

Corporate Governance

Related Party Transactions

• Purchase of a $3,210,000 senior secured convertible promissory note and warrants by the Philip & Daniele Barach Family Trust from Celularity Inc.
• Option for the Trust to purchase up to an additional $2,915,531 in convertible notes and warrants from Celularity Inc.
• Philip Barach, a trustee of the Trust, appointed to Celularity Inc.'s board of directors.
• Board Rights Agreement granting the Trust the right to designate two directors on Celularity Inc.'s five-person board.
• Amendment and restatement of a prior convertible note and warrants issued by Celularity Inc. to the Trust, with adjusted terms.

Stakeholder Impact

• Shareholders: Potential for dilution due to convertible notes and warrants, but also potential for increased company value if financing leads to successful development. Increased board influence by the Trust may alter strategic direction.
• Creditors: The Trust and other purchasers of convertible notes are now senior secured creditors, with a first-priority security interest over substantially all of the Company's assets.
• Management/Board: Increased oversight and potential influence from the Trust's designated directors. Spending is contingent on board composition meeting agreement terms.

Next Steps

• The Trust may exercise its option to purchase additional convertible notes and warrants by September 30, 2027.
• The Company is obligated to file a registration statement for the Trust's securities within 45 days of the effective date, aiming for effectiveness within 90-120 days.
• The Reporting Persons will continue to evaluate the Company's prospects and may adjust their investment strategy.

Key Dates

Recommendation

The filing indicates a significant financing event and increased board control for the Barach Trust, which is positive for their investment. However, the reliance on convertible debt and potential for future dilution suggest a 'hold' recommendation, pending further operational progress and clarity on the company's path to profitability.

Keywords

Celularity Inc., Schedule 13D, Convertible Note, Warrants, Financing, Board Representation, Beneficial Ownership, Securities Purchase Agreement